Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Cardiovascular Effects of Exposure to Ozone (MOSES)

8 juni 2012 uppdaterad av: Health Effects Institute

Multicenter Ozone Study in Elderly Subjects

The Multicenter Ozone Study in Elderly Subjects will investigate whether short-term exposure of elderly volunteers to ambient levels of ozone in a controlled exposure setting causes acute cardiovascular responses as assessed by changes in blood pressure, cardiac function, and systemic biomarkers of inflammation, endothelial dysfunction, and thrombosis.

Studieöversikt

Status

Okänd

Betingelser

Detaljerad beskrivning

This multicenter study will investigate whether short-term exposure of elderly volunteers to ambient levels of O3 in a controlled exposure setting while intermittently exercising causes acute cardiovascular responses. The study is based on the suppositions that: 1) elderly people are a susceptible group for cardiovascular effects; and 2) effects are more likely with exercise.

The study will involve approximately 90 healthy volunteers aged ≥55 and ≤70 who meet strict criteria for inclusion. They will be exposed for 3 hours to clean air, 0.07 ppm O3 (near the current NAAQS), and 0.12 ppm O3 (a level measured in several locations in the US). A suite of cardiovascular and pulmonary endpoints will be measured on the day before the exposure and up to 22 hours after the exposures. The study is being conducted at three centers using a common protocol and common SOPs. Most the endpoints will be analyzed by core laboratories to reduce the variability in the results. A Data Coordination and Analysis Center will assemble all the data generated by the three centers and conduct the statistical analyses on the combined data sets.

The study has 3 main objectives:

  1. To determine the relationship of altered autonomic balance (measured as changes in heart rate and heart rate variability (HRV)), cardiac arrhythmia, and repolarization and ozone exposure.
  2. To identify instances of altered systemic vascular function [measured as brachial artery flow-mediated dilation (FMD)without and with nitroglycerin (NTG) when exposed to ozone.
  3. To identify pro-thrombotic vascular state (measured as increase in von Willebrand factor antigen in blood - primary endpoints) when exposed to ozone.

Additional objectives include:

  1. To identify any increase in micro particle-associated tissues factor (measured as number of particles and tissue factor activity) and platelet activation) in ozone exposure.
  2. To identify if markers of systemic oxidative stress and inflammation and any correlation with the cardiovascular effects and degree of airway injury (measured as CC16) and airway inflammatory effects (neutrophils and cytokines in induced sputum) in ozone exposure.
  3. To determine if cardiovascular effects in ozone exposure are correlated with airway inflammatory effects, but not lung function effects.

Studietyp

Observationell

Inskrivning (Förväntat)

90

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • California
      • San Francisco, California, Förenta staterna, 94143
        • Rekrytering
        • University of California at San Francisco
        • Kontakt:
        • Huvudutredare:
          • John Balmes, MD
    • Massachusetts
      • Watertown, Massachusetts, Förenta staterna, 02472
        • Aktiv, inte rekryterande
        • New England Research Institutes, Inc.
    • New York
      • Rochester, New York, Förenta staterna, 14642
        • Rekrytering
        • University of Rochester
        • Kontakt:
        • Huvudutredare:
          • Mark Frampton, MD
    • North Carolina
      • Chapel Hill, North Carolina, Förenta staterna, 27599
        • Rekrytering
        • University of North Carolina at Chapel Hill
        • Kontakt:
        • Huvudutredare:
          • Philip Bromberg, MD

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

55 år till 70 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Healthy elderly volunteers living in or around San Francisco, CA, Research Triangle Park, NC, and Rochester, NY

Beskrivning

Inclusion Criteria:

  • males and females of all ethnic backgrounds.
  • Normal spirometry (FEV1 and FVC >75% of predicted and FEV1/FVC >0.65).
  • Ability to complete the exposure exercise regimen chosen to induce a ventilation rate of 15 to 17 L/min/m2 without exceeding 80% of predicted maximal heart rate.
  • Normal baseline 12-lead resting ECG, and absence of significant ST depression while performing the 15-minute required level of exercise targeted for the exposure period.
  • Subjects must be able to avoid certain medication supplements listed for 1 week before the exposure.

Exclusion Criteria:

  • Non-English speaking.
  • Including, but not limited to as ascertained by the physicians: Subjects with chronic cardiovascular (such as ischemic heart disease) or respiratory (such as asthma or COPD) disease; diabetes, or other organ or system dysfunction; cerebrovascular disease; active psychiatric disorders that would interfere with the subject's ability to understand and participate in the study. Subjects who have tested positive for a disease that affects the immune system (such as HIV, lymphoma, leukemia) or current drug or alcohol abuse (defined as having more than 3 drinks per day or being unable to abstain from alcohol for 3 days).
  • Subjects with atopy or allergic rhinitis will not be excluded as long as they do not require regular treatment with antihistamines or systemic steroids.
  • Ever-smokers (smoked tobacco or marijuana during the last five years, or with history of >10 pack year for tobacco or > 1 joint year for marijuana, or living with a smoker who smokes inside the house).
  • Subject having plasma cotinine level > 3ng/mL.
  • BMI >35 or <18 (35 is the official cut off for class 1 obesity).
  • Hypertension (defined as blood pressure >140 systolic or >90diastolic) or on anti-hypertension medications other than diuretics.
  • Pregnancy or nursing (breastfeeding).
  • On the following medications: prednisone, statins, beta-blockers, anticoagulants, current hormonal therapy, tamoxifen. Subjects will not be asked to discontinue needed prescription medications for the purpose of this study. If any of these medications becomes necessary during the course of the study, the subjects will be excluded. Use of other medications will be considered on an individual basis.
  • Subjects taking aspirin or PDE5 inhibitors must be willing to abstain from these medications during the week preceding each exposure.
  • Occupational exposures (exposed to high levels of vapors, dust, gases, or fumes on an on-going basis)

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Tidsperspektiv: Blivande

Kohorter och interventioner

Grupp / Kohort
elderly subjects
Healthy

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in endothelial function
Tidsram: Baseline (16 hours before exposure) and 4 hours after exposure
Brachail artey flow-mediated dilation and nitroglycerin-mediated dilation
Baseline (16 hours before exposure) and 4 hours after exposure
Change in heart rate variability
Tidsram: Baseline (0.5 hours before exposure) and 0.2, 2, and 21.5 after exposure
measured with Holter monitor
Baseline (0.5 hours before exposure) and 0.2, 2, and 21.5 after exposure
Change in prothrombotic vascular state
Tidsram: Baseline (17 hour before exposure) and 3.5 and 22 hours after exposure
Peripheral blood samples will be taken and stored as plasma for measurement of von Willenbrand Factor antigen
Baseline (17 hour before exposure) and 3.5 and 22 hours after exposure
Change in cardiac repolarization
Tidsram: Baseline (0.5 hours before exposure) and 0.2, 2, and 21.5 after exposure
from Holter monitor
Baseline (0.5 hours before exposure) and 0.2, 2, and 21.5 after exposure

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in markers of systemic inflammation
Tidsram: Baseline (17 hour before exposure) and 3.5 and 22 hours after exposure
Peripheral blood samples will be taken and stored as plasma for measurements of inflammatory markers
Baseline (17 hour before exposure) and 3.5 and 22 hours after exposure
Change in lung function
Tidsram: Baseline (0.2 hours before exposure) and 0.5, 3, and 22.5 hours after exposure
Spirometry
Baseline (0.2 hours before exposure) and 0.5, 3, and 22.5 hours after exposure
Lung inflammation
Tidsram: 22 hours after exposure
A sputum sample will be obtained and stored for measurement of inflammatory mediators
22 hours after exposure

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 januari 2012

Primärt slutförande (Förväntat)

1 december 2014

Avslutad studie (Förväntat)

1 december 2014

Studieregistreringsdatum

Först inskickad

1 december 2011

Först inskickad som uppfyllde QC-kriterierna

5 december 2011

Första postat (Uppskatta)

7 december 2011

Uppdateringar av studier

Senaste uppdatering publicerad (Uppskatta)

11 juni 2012

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

8 juni 2012

Senast verifierad

1 juni 2012

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • 10-01-4

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera